We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Manufacturers Challenge Canada's Exclusivity Protection
Calling the impact of recent regulatory amendments to Canada’s drug patent rules “unnecessary and costly to taxpayers,” generic drug manufacturers led by the Canadian Generic Pharmaceutical Association (CGPA) are calling on a federal court to repeal modifications to federal regulations that provide brand manufacturers with eight years of freedom from generic drug competition.